Affimed N.V. has revealed the oral presentation of AFM28 data at the 66th ASH Annual Meeting and Exposition.

Electra Therapeutics Shares Favorable Phase 1b Trial Outcomes for ELA026 in sHLH During an ASH 2024 Oral Presentation.

Immune-Onc Therapeutics Reveals Latest Phase 1b Trial Results for IO-202, Showcasing Positive Efficacy and Safety in CMML Patients, at the 2024 ASH Meeting.

Star Therapeutics Unveils Midpoint Clinical Results for VGA039 in VWD Patients at 2024 ASH Conference.

Auron Therapeutics has released data on its primary project, AUTX-703, at the 66th ASH Annual Meeting and Exposition in San Diego, CA.

Corbus Pharmaceuticals Begins First Human Trial of CRB-601 for Advanced Solid Tumors, Marking First Patient Dosed.

siRNA (small interfering RNA) drugs and ASO (antisense oligonucleotide) drugs, as the two pillars of the small nucleic acid therapeutics field.

Solu Therapeutics Reveals Favorable Preclinical Findings for STX-0712 in Treating Chronic Myelomonocytic and Acute Myeloid Leukemias at the ASH Conference.

Seismic Therapeutic Unveils Fresh Preclinical Efficacy Results for S-1117 in Preventive and Treatment Animal Models of Immune Thrombocytopenia at the 66th ASH Meeting.

Molecular Targeting Technologies, Inc. (MTTI) has released preclinical research findings for their proprietary 225Ac-EBTATE targeting SSTR2-positive neuroendocrine tumors (NET).

Merck Reports Phase 3 KEYLYNK-001 Study Achieves Main Goal of Progression-Free Survival in Advanced Ovarian Cancer Patients.

Molecular Partners Unveils Clinical Findings for MP0533 Study and Preclinical Insights on MP0621 at ASH 2024, Advancing Their Research Agenda.